darexaban + naproxen

darexaban + naproxen refers to the co-administration of two drugs: darexaban, an oral direct Factor Xa inhibitor (anticoagulant, code name YM150), and naproxen, a non-steroidal anti-inflammatory drug (NSAID) commonly used for pain and inflammation. Darexaban acts by selectively and reversibly inhibiting Factor Xa, thereby preventing thrombin generation and clot formation. Naproxen acts as a non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis and thus inflammation and pain. The combination is not a commercial fixed-dose combination product but may be studied or used together in clinical settings, for example, in patients with conditions requiring both anticoagulation and pain/inflammation management. Clinical studies of similar combinations (e.g., rivaroxaban + naproxen, edoxaban + naproxen) have shown increased bleeding risk due to additive effects on hemostasis, but no clinically relevant pharmacokinetic interaction[1][2][3].